CMPCPS 001
Alternative Names: CMP-CPS-001Latest Information Update: 05 Apr 2024
At a glance
- Originator CAMP4 Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Carbamoyl phosphate synthase (ammonia) expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inborn urea cycle disorders
Most Recent Events
- 12 Feb 2024 Phase-I clinical trials in Inborn urea cycle disorders (In volunteers) in Australia (SC) (NCT06247670)